pyridoxine has been researched along with Arteriosclerosis in 104 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To establish guidelines for the screening and treatment of hyperhomocysteinemia in the investigation and management of coronary artery disease (CAD)." | 8.80 | Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. ( Booth, GL; Wang, EE, 2000) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | 7.71 | Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Hyperhomocysteinemia has been identified as a potential risk factor for atherosclerosis." | 7.70 | Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) ( Beilby, JP; Hung, J; McQuillan, BM; Nidorf, M; Thompson, PL, 1999) |
| "Moreover, mild hyperhomocysteinemia has been shown to be associated with a 2 to 4-fold increased relative risk for coronary artery disease, cerebrovascular disease, and peripheral arterial occlusive disease." | 6.40 | [Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis]. ( Solenthaler, M; Wuillemin, WA, 1999) |
| " In this article we review the main theories of atherosclerosis which take into account the proteins, namely homocysteine, homocysteine metabolism, the cause that may be responsible for high levels of homocysteinemia, the pathophysiologic mechanisms of vascular lesion induced by hyperhomocysteinemia, the clinical evidence that homocysteinemia constitutes a vascular risk factor and finally, the evidence that it is possible to control homocysteinemia with supplementation of co-factors of homocysteine metabolism, namely vitamin B6, B12 or folic acid." | 4.80 | [Homocysteinemia and vascular disease--a new risk factor is born]. ( Luís, AS; Reis, RP, 1999) |
| "To establish guidelines for the screening and treatment of hyperhomocysteinemia in the investigation and management of coronary artery disease (CAD)." | 4.80 | Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. ( Booth, GL; Wang, EE, 2000) |
| "Hyperhomocysteinemia refers to an elevated circulating level of the sulfur-containing amino acid homocysteine and has been shown to be a risk factor for vascular disease in the general population." | 4.80 | Homocysteine and renal disease. ( Robinson, K; van Guldener, C, 2000) |
| "Using an atherogenic diet that produces both hyperhomocysteinemia and hypercholesterolemia, we tested the hypothesis that dietary supplementation with B vitamins (folic acid, vitamin B(12), and vitamin B(6)) would prevent hyperhomocysteinemia, vascular dysfunction, and atherosclerotic lesions in monkeys." | 3.71 | Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. ( Heistad, DD; Lentz, SR; Malinow, MR; Piegors, DJ, 2001) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | 3.71 | Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Hyperhomocysteinemia has been identified as a potential risk factor for atherosclerosis." | 3.70 | Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) ( Beilby, JP; Hung, J; McQuillan, BM; Nidorf, M; Thompson, PL, 1999) |
| "Hyperhomocysteinemia has been increasingly recognized as an important risk factor for elevated atherosclerotic vascular disease in chronic renal failure." | 3.70 | [Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement]. ( Graefe, U; Henning, BF; Tepel, M; Zidek, W, 2000) |
| " Pyridoxine was found to increase the growth rate of cell cultures from a patient with pyridoxineresponsive homocystinuria and to increase the production of fibrillar proteoglycan by the cells; no effect of pyridoxine was observed in the cell cultures from a patient who failed to respond to pyridoxine therapy." | 3.65 | Macromolecular basis for homocystein-induced changes in proteoglycan structure in growth and arteriosclerosis. ( McCully, KS, 1972) |
| "Causes of hyperhomocysteinemia are hereditary heterozygous or, in very rare cases, homozygous defects, and quite frequently a lack of the coenzymes B6 and B12 and the cosubstrate folate." | 2.41 | Homocysteine--relevant for atherogenesis? ( Kircher, T; Sinzinger, H, 2000) |
| "Homocystinuria is an uncommon genetic disease characterized by a marked increase of serum homocysteine (HCY), an intermediate of methionine metabolism." | 2.40 | [Homocysteine and cardiovascular risk]. ( Chapelle, JP; Gielen, J; Lutteri, L, 1999) |
| "Moreover, mild hyperhomocysteinemia has been shown to be associated with a 2 to 4-fold increased relative risk for coronary artery disease, cerebrovascular disease, and peripheral arterial occlusive disease." | 2.40 | [Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis]. ( Solenthaler, M; Wuillemin, WA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 52 (50.00) | 18.7374 |
| 1990's | 39 (37.50) | 18.2507 |
| 2000's | 13 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| RINEHART, JF | 2 |
| GREENBERG, LD | 3 |
| Marcucci, R | 1 |
| Zanazzi, M | 1 |
| Bertoni, E | 1 |
| Rosati, A | 1 |
| Fedi, S | 1 |
| Lenti, M | 1 |
| Prisco, D | 1 |
| Castellani, S | 1 |
| Abbate, R | 1 |
| Salvadori, M | 1 |
| MCFARLAND, W | 1 |
| BALAGUER-VINTRO, I | 1 |
| NOLLA-PANADES, J | 1 |
| DE ORUS-NAVARRO, J | 1 |
| MENINI, E | 1 |
| GIBERT-QUERALTO, J | 1 |
| ABITBOL, L | 1 |
| VILLEA, AA | 1 |
| PEREIRA, AF | 1 |
| MOTOYASU, M | 1 |
| SUKASOVA, MI | 1 |
| CASTELLO, S | 1 |
| SALVATORE, V | 1 |
| KNUECHEL, F | 1 |
| ALEKSEEVA, AS | 1 |
| NEKRASOVA, AA | 1 |
| MAZZEI, ES | 1 |
| MAZZEI, CM | 1 |
| MARKIEWICZ, M | 1 |
| ASTENGO, F | 1 |
| BESTAGNO, M | 1 |
| LUKOMSKII, PE | 1 |
| ERLANDE, G | 1 |
| WAREMBOURG, H | 1 |
| BERTRAND, M | 1 |
| COLSON, JA | 1 |
| GALLAY, C | 1 |
| WOHL, H | 1 |
| MERSKEY, C | 1 |
| MENESESHOYOS, J | 1 |
| VERDONK, G | 2 |
| Spence, JD | 2 |
| Kheim, T | 1 |
| Kirk, JE | 2 |
| Jezková, Z | 1 |
| Pokorný, J | 1 |
| Smolin, LA | 1 |
| Crenshaw, TD | 1 |
| Kurtycz, D | 1 |
| Benevenga, NJ | 1 |
| Braunshteĭn, AE | 1 |
| Boushey, CJ | 1 |
| Beresford, SA | 1 |
| Omenn, GS | 1 |
| Motulsky, AG | 1 |
| Glueck, CJ | 1 |
| Shaw, P | 1 |
| Lang, JE | 1 |
| Tracy, T | 1 |
| Sieve-Smith, L | 1 |
| Wang, Y | 1 |
| Ubbink, JB | 1 |
| van den Berg, M | 3 |
| Franken, DG | 1 |
| Boers, GH | 3 |
| Blom, HJ | 1 |
| Jakobs, C | 3 |
| Stehouwer, CD | 4 |
| Rauwerda, JA | 4 |
| van der Griend, R | 2 |
| Meuwissen, OJ | 2 |
| Bergmark, C | 1 |
| Mansoor, MA | 1 |
| Swedenborg, J | 1 |
| de Faire, U | 1 |
| Svardal, AM | 1 |
| Ueland, PM | 1 |
| Bierdrager, E | 1 |
| McCully, KS | 2 |
| Chauveau, P | 1 |
| Chadefaux, B | 1 |
| Coudé, M | 1 |
| Aupetit, J | 1 |
| Kamoun, P | 1 |
| Jungers, P | 1 |
| Meleady, RA | 1 |
| Mulcahy, DA | 1 |
| Graham, IM | 1 |
| Robinson, K | 5 |
| Gupta, A | 2 |
| Dennis, V | 1 |
| Arheart, K | 2 |
| Chaudhary, D | 1 |
| Green, R | 2 |
| Vigo, P | 1 |
| Mayer, EL | 1 |
| Selhub, J | 3 |
| Kutner, M | 1 |
| Jacobsen, DW | 2 |
| Dennis, VW | 1 |
| Konecky, N | 1 |
| Malinow, MR | 5 |
| Tunick, PA | 1 |
| Freedberg, RS | 1 |
| Rosenzweig, BP | 1 |
| Katz, ES | 1 |
| Hess, DL | 1 |
| Upson, B | 1 |
| Leung, B | 1 |
| Perez, J | 1 |
| Kronzon, I | 1 |
| Shimakawa, T | 1 |
| Nieto, FJ | 1 |
| Chambless, LE | 1 |
| Schreiner, PJ | 1 |
| Szklo, M | 1 |
| Bostom, AG | 2 |
| Gohh, RY | 1 |
| Tsai, MY | 1 |
| Hopkins-Garcia, BJ | 1 |
| Nadeau, MR | 2 |
| Bianchi, LA | 1 |
| Jacques, PF | 2 |
| Rosenberg, IH | 2 |
| Shemin, D | 1 |
| Verhoef, P | 1 |
| Dworkin, L | 1 |
| Lentz, SR | 2 |
| Piegors, DJ | 2 |
| Bhopatkar-Teredesai, M | 1 |
| Faraci, FM | 1 |
| Heistad, DD | 2 |
| Peterson, JC | 1 |
| Refsum, H | 1 |
| Brattström, L | 1 |
| Boers, G | 1 |
| Ueland, P | 1 |
| Rubba, P | 1 |
| Palma-Reis, R | 1 |
| Meleady, R | 1 |
| Daly, L | 1 |
| Witteman, J | 1 |
| Graham, I | 1 |
| Moustapha, A | 1 |
| Goormastic, M | 1 |
| Tuzcu, EM | 1 |
| Hobbs, R | 1 |
| Young, J | 1 |
| James, K | 1 |
| McCarthy, P | 1 |
| van Lente, F | 1 |
| Dierkes, J | 1 |
| Kroesen, M | 1 |
| Pietrzik, K | 3 |
| Brouwer, DA | 1 |
| Welten, HT | 1 |
| van Doormaal, JJ | 2 |
| Reijngoud, DJ | 1 |
| Muskiet, FA | 1 |
| Brönstrup, A | 1 |
| Jensen, OK | 1 |
| Ingerslev, J | 1 |
| Cheng, TO | 1 |
| Cattaneo, M | 1 |
| Haas, FJ | 1 |
| Biesma, DH | 1 |
| Duran, M | 1 |
| Banga, JD | 1 |
| McQuillan, BM | 1 |
| Beilby, JP | 1 |
| Nidorf, M | 1 |
| Thompson, PL | 1 |
| Hung, J | 1 |
| de Jong, SC | 2 |
| Kostense, PJ | 1 |
| Alders, D | 1 |
| Pals, G | 1 |
| Lubbers, MF | 1 |
| Aarnoudse, JG | 1 |
| Reis, RP | 1 |
| Luís, AS | 1 |
| Lutteri, L | 1 |
| Chapelle, JP | 1 |
| Gielen, J | 1 |
| Wuillemin, WA | 1 |
| Solenthaler, M | 1 |
| Constans, J | 1 |
| Weiss, N | 1 |
| Keller, C | 1 |
| Li, W | 1 |
| Zheng, T | 1 |
| Wang, J | 1 |
| Altura, BT | 1 |
| Altura, BM | 1 |
| Vermeulen, EG | 1 |
| Erix, P | 1 |
| Twisk, JW | 1 |
| Witjes, RJ | 1 |
| Booth, GL | 1 |
| Wang, EE | 1 |
| Kircher, T | 1 |
| Sinzinger, H | 1 |
| van Guldener, C | 1 |
| Henning, BF | 1 |
| Tepel, M | 1 |
| Graefe, U | 1 |
| Zidek, W | 1 |
| Naruszewicz, M | 1 |
| Klinke, M | 1 |
| Dziewanowski, K | 1 |
| Staniewicz, A | 1 |
| Bukowska, H | 1 |
| Hofmann, MA | 1 |
| Lalla, E | 1 |
| Lu, Y | 1 |
| Gleason, MR | 1 |
| Wolf, BM | 1 |
| Tanji, N | 1 |
| Ferran, LJ | 1 |
| Kohl, B | 1 |
| Rao, V | 1 |
| Kisiel, W | 1 |
| Stern, DM | 1 |
| Schmidt, AM | 1 |
| Chambers, JC | 1 |
| Kooner, JS | 1 |
| McGregor, DO | 1 |
| Dellow, WJ | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Robson, RA | 1 |
| Chambers, ST | 1 |
| Levene, CI | 2 |
| Murray, JC | 1 |
| Mozhaĭtsev, BN | 1 |
| Vijayammal, PL | 1 |
| Kurup, PA | 1 |
| Krishnaswamy, K | 1 |
| Rao, SB | 1 |
| Lipkan, GN | 1 |
| Umovist, NM | 1 |
| Pike, S | 1 |
| Prati, RC | 1 |
| Cochran, C | 1 |
| Gorman, MA | 1 |
| Ashby, J | 1 |
| Liepa, GU | 1 |
| Merrill, AH | 1 |
| Henderson, JM | 1 |
| Serfontein, WJ | 1 |
| de Villiers, LS | 1 |
| Ubbink, J | 1 |
| Rapley, C | 1 |
| Koumans, AK | 1 |
| Wildschut, AJ | 1 |
| Sadoian, VS | 1 |
| Asatrian, AB | 1 |
| Agaronian, OSh | 1 |
| Braginskii, BM | 1 |
| Artaeva, LP | 1 |
| Modzelewski, A | 2 |
| Straczkowski, W | 2 |
| György, P | 1 |
| Brieger, H | 1 |
| De Lorenzi, F | 1 |
| Coon, WW | 1 |
| Nagler, E | 1 |
| Calabrese, L | 1 |
| Montagnani, I | 1 |
| Petrova, NP | 1 |
| Chernova, AI | 1 |
| Pol, G | 1 |
| den Hartog, C | 1 |
| Meyknecht, EA | 1 |
| Golikov, AP | 1 |
| Voog, R | 1 |
| Phelip, X | 1 |
| Blok, YE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on Therapeutic Effect of Treating Mental Stress Induced Myocardial Ischemia With Conventional Therapy for Coronary Heart Disease Combined With Traditional Chinese Medicine :Design and Methods[NCT02135250] | 120 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| 5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients[NCT00626223] | 341 participants (Actual) | Interventional | 1998-01-31 | Completed | |||
| A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI[NCT01704599] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to side effect and poor clinical outcome) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in EKG ( normalize, unchanged, became abnormal) when homocysteine (Hcy) increased or decreased from week 16 on adalimumab to week 28 on adalimumab plus folic acid, vitamins B6 and B12 in adault psoriasis patients ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 to Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| normalize when Hcy increased | unchanged when Hcy decreased | became abnormal when Hcy decreased | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 2 | 1 |
Change in CBC parameter: white blood count or hemoglobin or hematocrit ( as measured week 16 on adalimumab and at week 28 after 12 more weeks on adalimuamb , folic acid, B6 and B12) in adults ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| WBC increased | WBC unchanged | WBC decreased | Hemoglobin/Hematocrit increased | Hemoglobin/Hematocrit unchanged | Hemoglobin/Hematocrit decreased | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 0 | 2 | 3 | 0 | 2 |
"Worsening psoriasis or development or worsening of measured condition or new pathology not seen by week 16 but developed at weeks 28 or first discoved by telephone call day 70 post study:~AE Humira only" (NCT01704599)
Timeframe: After Week 16 of study
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Adverse Event after Week 16 | Adverse Event Weeks 16-28 | Adverse event by Day 70 call after Week 28 | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 4 | 1 |
A serious adverse event is hosptalization or death or pathology leading to early termination of a participant from the study. This was to be reported at anytime during the 28 week study of adult patients ages 18-65 with moderate to severe plaque psoriasis though categorized by Week 16 (on adalimumab alone, by Week 28 (on adalimuamb plus 3 B vitaminsand by day 70 post Week 28. (NCT01704599)
Timeframe: By Week 16, by Week 28 and by Day 70 post Week 28.
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No SAE | SAE by Week 16 | SAE by Week 28 | SAE by Day 70 afterWeek 28 | |
| Humira Then Humira Plus 3 B Vitamins | 7 | 1 | 0 | 0 |
An electrocardiogram (EKG) is used to evaluate the electrical activity of the heart by converting this activity into line tracings on paper.. Electrodes (small, plastic patches) are placed at certain locations on the chest, arms, and legs. When the electrodes are connected to an EKG machine by lead wires, the electrical activity of the heart is measured, interpreted, and printed out for the doctor's information and further interpretation. This test was to be administered to adults age 18 or older with moderate to severe plaque psoriasis patients at week 0, 16 and week 28 of this study. (NCT01704599)
Timeframe: Week 16 and then Week 28 after another 12 weeks on Humira plus vitamins and if early termination
| Intervention | participants (Number) | ||
|---|---|---|---|
| Normalizing | Unchanged | Newly abnormal | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 4 | 1 |
Height is the distance from the bottom (soles of feet ) to the top (top of head) of a person when that person is standing in this study using ruler in inches.Participants measured were adults age 18 or older with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 0 at Start of Adalimumab
| Intervention | participants (Number) | |
|---|---|---|
| Measured | Not measured | |
| Humira Then Humira Plus 3 B Vitamins | 8 | 0 |
Number of participants with a category change in Physician static Global Assessment (sPGA): 7 point score from 0 (clear) to 6 measuring amount of surface covered and plaque qualities: thickness & erythema plus scaling. Dynamic score compares baseline with either improvement/ worsening of the same factors measured in the sPGA using the 0-6 scoring range but focused on change. sPGA at weeks 16 AND 28. dynamic PGA to be categoically measured at.weeks16 and 28. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 1 | 3 |
DLQI is 10 questions examining impact of skin disease on quality of life: (1) symptoms & feelings (2) daily activities (3) leisure (4) work & school (5) personal relationship (6) treatment. To be administered to adults over 18 years with moderate to severe plaque psoriasis at week 0 (no systemic psoriasis medication);. weeks 16 ( after 16 weeks of adalimumab) and week 28 (after 16 weeks adalimumab then 12 weeks of adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12). (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 3 | 1 |
Serum folic acid level in adults ages 18 and older with mild to moderate plaque psoriasis measured at week 16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab plus 12 weeks of adalimumab and daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Increased | Unchanged | Decreased | Not evaluable (if >20 ng/ml only stated as such) | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 0 | 0 | 2 |
Adult particpants ages 18 or older with moderate to severe plaque psoriasis were to have serum VEGF measured at week 0 on no systemic psoriasis medication then at both weeks 16 on adalimumab and at week 28 on adalimumab plus folic acid, B6 and Vitamin B12. Subjects raniked by BMI week 0 low to high (NCT01704599)
Timeframe: At Screening visit, Week 16 on Humira, after another 12 weeks on Humira plus vitamins and if early termination
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 1 |
Adult participants 18 years or older with moderate to severe plaque psoriasis were to have serum B12 levels measures Weeks 0 (on no systemic psoriasis medication), 16 (on adalimumab) and week 28 (on adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12. (NCT01704599)
Timeframe: At Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 5 | 0 | 0 |
Using a thermometer for body temperature on degrees Fahrenheit. Participants to be measured were adults 18 years or older with moderate to severe plaque psoriasis with temperature to be measured at week 16 16 weeks of adalimumab and week 28 after 16 weeks of adalimumab then 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| increased | unchanged | decreased | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 2 | 1 |
Adult participants age 18 years or older with moderate to severe plaque psoriasis with serum IgG antibodies against Helicobacter pylori bacteria using commercial ELISA assay during the 28 week study. (NCT01704599)
Timeframe: Week 28 after 16 weeks of Adalimumab then 12 of Adalimumab-Vitamins
| Intervention | participants (Number) | |
|---|---|---|
| Elevated | Normal | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 6 |
Weight is how heavy a participant is. Weight in pounds of each study adult participant age 18-65 years with moderate to severe plaque psoriasis measured at weeks 16 and compared to week 28 of study. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 0 | 5 |
Blood pressure is the force the heart exerts against the walls of arteries as it pumps the blood out to the body. The unit of measurement is millimeters of mercury (mm Hg). Pulse is the number of times your heart beats per minute. The unit of measurement is beats per minute (BPM). These test measurements compared in adults with moderate to severe plaque psoriasis week 16 after 16 weeks adalimumab and week 28 after 16 weeks adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg vitamin B12. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Systolic BP increased | Systolic BP unchanged | Systolic BP decreased | Diastolic BP increased | Diastolic BP unchanged | Diastolic BP decreased | Pulse increased | Pulse unchanged | Pulse decreased | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 3 | 5 | 0 | 2 | 5 | 0 | 2 |
Serum homocysteine measured at week 16 after 16 weeks of adalimumab and week 28 after 16 weeks of adalimumaband then 12 weeks of adalimumab plus 5 mg folic acid, 100mg B6 and 1000 mcg of B12 in adults ages 18-65 with moderate to sever plaque psoriasis.. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Plus 3 B Vitamins | 1 | 0 | 3 |
Serum magnesium (Mg) was to be measured at baseline, Week 16 (on adalimumab) and at week 28 (on adalimumab plus folic acid, vitamins B6 and B12) in adult participants age 18 or older with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 2 | 2 |
Serum phosphorus (P) levels were to be measured weeks16 and 28 in adult participants age 18 and older with moderate to severe plaque psoriasis at week 0 on no systemic psoriasis medication; week 16 after 16 weeks of adalimumab and at week 28 after 16 weeks of adalimumab plus 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12. (NCT01704599)
Timeframe: Week 16 then Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 0 | 2 |
Serum vitamin B6 levels were to be measured weeks16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab and 12 weeks on adalimuamb, folic acid 5 mg, b6 100 mg and B12 1000 mcg in adult participants with moderate to sever plque psoriasis. (NCT01704599)
Timeframe: At Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 0 |
Women of childbearing years over age 18 with moderate to severe plaque psoriasis on no systemic therapy at week 0 of study. (NCT01704599)
Timeframe: At screening
| Intervention | participant (Number) | |
|---|---|---|
| Negative | Positive | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 0 |
PASI: formula based on body surface areas on head/neck, trunk, both arms & legs with disease quality grading induration, scale and erythema on participants ages 18-65 with moderate to severe plaque psoriasis measured at weeks 16 and 28. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 1 | 2 |
Baseline VEGF level at week zero related to PASI change Week 16 on adalimumab compared to Week 28 after additonal 12 weeks of adalimumab plus folic acid, vitamin B6 and B12 in adult psoriasis patients ages 18-65 with moderate to severe plaque psoriasis.High levels were greater than or equal to 140 pg/ml. Normal VEGF was below this level. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| PASI improved with high VEGF | PASI Worsened with high VEGF | PASI Unchanged with normal VEGF | PASI Improved with normal VEGF | PASI Worsened with normal VEGF | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 2 | 1 | 3 | 0 |
Change in PASI from Week 16 on adalimumab to Week 28 on adalimumab, folic acid, vitamin B6 and B12 in adults ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| BMI >27.3 who improved | BMI >27.3 who worsened | BMI of 27.3 who were unchanged | BMI<27.3 who improved | BMI<27.3 who worsened | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 0 | 0 | 2 |
Change in PASI from Week 16 after 16 weeks of adalimumab to Week 28 after another 12 weeks of adalimumab plus folic acid, vitamins B6 and B12 and Change reported by telephone 70 days after week 28 (NCT01704599)
Timeframe: Week 16 to Week 28 and Week 28 to post study day 70
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| high titer worsened | high titer improved then worsened day 70 | normal titer improved | normal titer unchanged then improved day 70 | normal titer worsened | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 1 | 3 | 1 | 1 |
23 reviews available for pyridoxine and Arteriosclerosis
| Article | Year |
|---|---|
[DRUGS LOWERING THE CHOLESTEROL LEVEL IN THE BLOOD].
Topics: Antimetabolites; Arteriosclerosis; Ascorbic Acid; Cholesterol; Choline; Corrinoids; Ethyl Biscoumace | 1963 |
ARTERIOSCLEROTIC, DENTAL AND HEPATIC LESIONS IN PYRIDOXINE-DEFICIENT MONKEYS.
Topics: Animals; Arteriosclerosis; Dental Caries; Haplorhini; Liver; Pathology; Pyridoxine; Vitamin B 6 Defi | 1964 |
Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go?
Topics: Arteriosclerosis; Clinical Trials as Topic; Dipeptides; Folic Acid; Homocysteine; Homocystine; Human | 2001 |
[Clinical significance of amino acid transformations as affected by pyridoxal phosphate enzymes].
Topics: Amino Acid Metabolism, Inborn Errors; Amino Acids; Amino Acids, Essential; Animals; Arteriosclerosis | 1982 |
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.
Topics: Arteriosclerosis; Coronary Disease; Female; Folic Acid; Food, Fortified; Homocysteine; Humans; Male; | 1995 |
Vitamin nutrition status and homocysteine: an atherogenic risk factor.
Topics: Arteriosclerosis; Case-Control Studies; Coronary Disease; Folic Acid; Homocysteine; Humans; Nutritio | 1994 |
Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease.
Topics: Arteriosclerosis; Betaine; Coronary Disease; Folic Acid; Heterozygote; Homocysteine; Homocystinuria; | 1994 |
Homocysteine and vascular disease.
Topics: Arteriosclerosis; Diet; Folic Acid; Homocysteine; Humans; Pyridoxine; Risk Factors | 1996 |
Homocysteinemia and vascular disease in end-stage renal disease.
Topics: Arteriosclerosis; Female; Folic Acid; Homocysteine; Humans; Kidney; Kidney Failure, Chronic; Kidney | 1996 |
The role of homocysteine, folate and other B-vitamins in the development of atherosclerosis.
Topics: Arteriosclerosis; Coronary Disease; Folic Acid; Hematinics; Homocysteine; Humans; Middle Aged; Pyrid | 1997 |
[Increased p-homocysteine--a risk factor for thrombosis].
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Female; Folic Acid; Homocysteine; Humans; Male; Middle A | 1998 |
Hyperhomocysteinemia, atherosclerosis and thrombosis.
Topics: Adult; Aged; Animals; Arteriosclerosis; Avitaminosis; Case-Control Studies; Clinical Trials as Topic | 1999 |
[Homocysteinemia and vascular disease--a new risk factor is born].
Topics: Arteriosclerosis; Cardiovascular Diseases; Folic Acid; Humans; Hyperhomocysteinemia; Pyridoxine; Ris | 1999 |
[Homocysteine and cardiovascular risk].
Topics: Arteriosclerosis; Cardiovascular Diseases; Folic Acid; Homocystinuria; Humans; Hyperhomocysteinemia; | 1999 |
[Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis].
Topics: Arteriosclerosis; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Pyridoxine; Risk Factors; | 1999 |
[Hyperhomocysteinemia, a risk factor for atherosclerosis: causes and effects].
Topics: Age Factors; Arterial Occlusive Diseases; Arteriosclerosis; Cerebrovascular Disorders; Coronary Dise | 1999 |
Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.
Topics: Aged; Arteriosclerosis; Canada; Coronary Disease; Dietary Supplements; Disease Susceptibility; Fasti | 2000 |
Homocysteine--relevant for atherogenesis?
Topics: Arteriosclerosis; Case-Control Studies; Coronary Disease; Folic Acid; Hematinics; Humans; Hyperhomoc | 2000 |
Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease.
Topics: Arteriosclerosis; Case-Control Studies; Clinical Trials as Topic; Comorbidity; Coronary Disease; Fol | 2000 |
Homocysteine and renal disease.
Topics: Adult; Arteriosclerosis; Cardiovascular Diseases; Case-Control Studies; Child; Endothelium, Vascular | 2000 |
Atherosclerosis--disease of old age or infancy?
Topics: Aging; Animals; Aorta; Arteriosclerosis; Collagen; Coronary Vessels; Elastic Tissue; Elastin; Humans | 1978 |
Diseases associated with defects in vitamin B6 metabolism or utilization.
Topics: Alkaline Phosphatase; Arteriosclerosis; Celiac Disease; Female; Hematologic Diseases; Humans; Kidney | 1987 |
Developments leading to the metabolic role of vitamin B 6.
Topics: Acrodynia; Adult; Aged; Aging; Amines; Animals; Arteriosclerosis; Aspartate Aminotransferases; Biolo | 1971 |
4 trials available for pyridoxine and Arteriosclerosis
| Article | Year |
|---|---|
Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients.
Topics: Adult; Arteriosclerosis; Carotid Arteries; Dietary Supplements; Double-Blind Method; Female; Folic A | 2003 |
Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Creatinine; Female; Folic Acid; Homocysteine; Huma | 1996 |
[Recommended dietary allowance of folic acid is insufficient for optimal homocysteine levels].
Topics: Adult; Aged; Arteriosclerosis; Dietary Supplements; Female; Folic Acid; Homocysteine; Humans; Male; | 1998 |
Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
Topics: Adult; Arteriosclerosis; Cholesterol; Creatinine; Drug Therapy, Combination; Female; Fibrinogen; Fol | 2001 |
77 other studies available for pyridoxine and Arteriosclerosis
| Article | Year |
|---|---|
Arteriosclerotic lesions in pyridoxine deficient monkeys.
Topics: Animals; Arteriosclerosis; Haplorhini; Pyridoxine; Vitamin B 6 Deficiency | 1948 |
Effect of high pyridoxine intake in cholesterol-fed chicks.
Topics: Animals; Arteriosclerosis; Chickens; Cholesterol; Lipid Metabolism; Pyridoxine; Vitamin B 6 | 1953 |
Role of phenylethyl-acetic acid, linoleic acid and pyridoxine in experimental atherosclerosis in the chick.
Topics: Acetates; Animals; Arteriosclerosis; Atherosclerosis; Chickens; Cholesterol; Linoleic Acid; Pyridoxi | 1958 |
[Clinical experiences with linoleic acid and pyridoxine in hypercholesterolemia].
Topics: Arachidonic Acid; Arteriosclerosis; Cholesterol; Hypercholesterolemia; Linoleic Acid; Nutrition Ther | 1960 |
[On the effect of the active form of vitamin B 6 on experimental arteriosclerosis in rabbits].
Topics: Animals; Arteriosclerosis; Pyridoxal Phosphate; Pyridoxine; Rabbits; Vitamin B 6 | 1963 |
[Treatment of atherosclerosis with the preparation Delipin].
Topics: Arteriosclerosis; Ascorbic Acid; Atherosclerosis; Humans; Methionine; Phenobarbital; Pyridoxine | 1962 |
[Action of a gastric mucin preparation and various vitamins on the most indicative hematochemical indices of atherosclerosis].
Topics: Arteriosclerosis; Ascorbic Acid; Atherosclerosis; Cholesterol; Gastric Mucins; Humans; Lipids; Niaci | 1963 |
[Effect of Lipokapsul on the serum lipids in arteriosclerosis (with reference to different diet forms)].
Topics: Arteriosclerosis; Coronary Disease; Diet; Diet Therapy; Fatty Acids; Fatty Acids, Essential; Humans; | 1962 |
CHANGES IN TRANSAMINASE ACTIVITY IN EXPERIMENTAL AND CLINICAL ATHEROSCLEROSIS.
Topics: Alanine Transaminase; Animals; Aorta; Arteriosclerosis; Aspartate Aminotransferases; Atherosclerosis | 1963 |
[ATHEROSCLEROSIS. RECENT ASPECTS OF ITS BIOCHEMISTRY, PATHOGENESIS AND CLINICAL FEATURES AND OF THE ACTION OF SOME HYPOCHOLESTEREMIC DRUGS].
Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Diet; Diet Therapy; Fatty Acids; Lipid Metabolism; L | 1963 |
[FINDINGS ON THE HYPOLIPEMIZING AND HYPOCHOLESTEROLEMIZING ACTION OF A NEW PHARMACOLOGIC ASSOCIATION].
Topics: Arteriosclerosis; Cholesterol; Fatty Acids; Lipids; Niacin; Nicotinic Acids; Pyridoxine; Rutin; Vita | 1963 |
[PROBLEMS IN DRUG THERAPY AND ATHEROSCLEROSIS PREVENTION].
Topics: Arteriosclerosis; Atherosclerosis; Choline; Fatty Acids; Folic Acid; Hematinics; Humans; Lipid Metab | 1963 |
[CLINICAL AND THERAPEUTIC STUDY OF A NEW BI-VITAMIN BIOCHEMICAL MOLECULE].
Topics: Anemia; Arteriosclerosis; Ascorbic Acid; Humans; Intracranial Arteriosclerosis; Liver Diseases; Ment | 1964 |
[CLINICAL STUDY OF A LIPOTROPIC FORMULA: ORNITAINE].
Topics: Alkaloids; Arteriosclerosis; Cholecystectomy; Cholesterol; Citrates; Lipids; Lipoproteins; Lipotropi | 1964 |
[TRIAL TREATMENT OF HEPATIC METABOLIC DISORDERS BY AN ORIGINAL FORMULA CONTAINING MAINLY ORNITHINE COMBINED WITH VARIOUS CLASSICAL LIPOTROPIC SUBSTANCES].
Topics: Alkaloids; Arteriosclerosis; Cholesterol; Citrates; Humans; Lipid Metabolism; Lipotropic Agents; Liv | 1964 |
ANEMIA IN RATS ON ATHEROGENIC DIETS.
Topics: Anemia; Arteriosclerosis; Cholesterol; Chromium Isotopes; Diet, Atherogenic; Dietary Fats; Erythrocy | 1964 |
[DRUGS AGAINST HYPERCHOLESTEROLEMIA].
Topics: Adrenal Cortex Hormones; Arteriosclerosis; Estrogens; Gonadal Steroid Hormones; Heparin; Humans; Hyp | 1964 |
THE INFLUENCE OF NUTRITIONAL AND PHARMACOLOGICAL FACTORS ON THE BLOOD LIPID PATTERN IN ATHEROSCLEROTIC DISEASE AND IN THE TREATMENT OF PEPTIC ULCER.
Topics: Androgens; Anticholesteremic Agents; Arteriosclerosis; Dextrothyroxine; Diet; Diet Therapy; Dietary | 1964 |
[BLOOD BIOCHEMICAL STUDY OF THE INFLUENCE OF FAT-RICH DIETS IN GASTROENTEROLOGY ON THE DEVELOPMENT OF ATHEROSCLEROSIS].
Topics: Arteriosclerosis; Atherosclerosis; Dextrothyroxine; Diet; Diet Therapy; Dietary Fats; Drug Therapy; | 1964 |
Arteriosclerotic lesions in pyridoxine-deficient monkeys.
Topics: Animals; Arteriosclerosis; Haplorhini; Pyridoxine; Vitamin B 6 Deficiency | 1949 |
Vitamin B6 content of human arterial and venous tissue.
Topics: Adolescent; Adult; Aged; Aorta; Arteriosclerosis; Biological Assay; Black or African American; Blood | 1967 |
The appearance of a wide variety of antibodies in atherosclerosis.
Topics: Aged; Antibody Formation; Arteriosclerosis; Blood Vessels; Cholesterol; Female; Heparin; Humans; Hya | 1967 |
Homocyst(e)ine accumulation in pigs fed diets deficient in vitamin B-6: relationship to atherosclerosis.
Topics: Animal Feed; Animals; Arteriosclerosis; Body Weight; Diet; Homocysteine; Male; Pyridoxine; Swine; Vi | 1983 |
Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients.
Topics: Aged; Analysis of Variance; Arteriosclerosis; Coronary Disease; Cystathionine; Folic Acid; Homocyste | 1995 |
Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia.
Topics: Adult; Arteriosclerosis; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; Humans; Male; | 1994 |
[Hyperhomocysteinemia as risk factor for premature atherosclerosis].
Topics: Amino Acid Metabolism, Inborn Errors; Arteriosclerosis; Homocysteine; Homozygote; Humans; Pyridoxine | 1994 |
Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50--effect of smoking and extent of disease.
Topics: Adult; Arteriosclerosis; Female; Folic Acid; Follow-Up Studies; Homocysteine; Humans; Ischemia; Male | 1993 |
Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease.
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Coronary Disease; Fasting; Female; Folic Acid; H | 1996 |
Genes, greens, and homocysteine.
Topics: Angina Pectoris; Arteriosclerosis; Folic Acid; Homocysteine; Humans; Myocardial Infarction; Prospect | 1996 |
Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.
Topics: Aged; Aging; Arteriosclerosis; Female; Folic Acid; Homocysteine; Humans; Kidney Failure, Chronic; Ma | 1996 |
Correlation between plasma homocyst(e)ine and aortic atherosclerosis.
Topics: Aged; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Echocardiography, Transesophageal; Female; | 1997 |
Vitamin intake: a possible determinant of plasma homocyst(e)ine among middle-aged adults.
Topics: Analysis of Variance; Arteriosclerosis; Carotid Arteries; Case-Control Studies; Diet; Female; Folic | 1997 |
Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients.
Topics: Adult; Aged; Arteriosclerosis; Fasting; Female; Folic Acid; Homocysteine; Humans; Kidney Failure, Ch | 1997 |
Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cohort Stud | 1997 |
Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys.
Topics: Acetylcholine; Adenosine Diphosphate; Animals; Arteriosclerosis; Carotid Arteries; Carotid Stenosis; | 1997 |
Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia.
Topics: Aged; Arteriosclerosis; Female; Folic Acid; Homocysteine; Humans; Male; Middle Aged; Pyridoxine; Vit | 1998 |
Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group.
Topics: Adult; Analysis of Variance; Arteriosclerosis; Avitaminosis; Case-Control Studies; Cerebrovascular D | 1998 |
High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients.
Topics: Arteriosclerosis; Biomarkers; Coronary Thrombosis; Female; Folic Acid; Folic Acid Deficiency; Follow | 1998 |
Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women.
Topics: Adult; Arteriosclerosis; Drug Interactions; Fasting; Female; Folic Acid; Homocysteine; Humans; Pyrid | 1998 |
Homocysteine, B vitamins, and atherosclerosis.
Topics: Animals; Arteriosclerosis; Homocysteine; Humans; Pyridoxine | 1999 |
Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives.
Topics: Adult; Age of Onset; Arteriosclerosis; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; | 1999 |
Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)
Topics: Adult; Aged; Amino Acid Substitution; Arteriosclerosis; Carotid Arteries; Carotid Stenosis; Comorbid | 1999 |
Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease.
Topics: Adult; Age Factors; Amino Acid Substitution; Arteriosclerosis; Body Mass Index; Comorbidity; Fasting | 1999 |
[Obstetric problems followed by stroke].
Topics: Abortion, Habitual; Adult; Arteriosclerosis; Cerebral Infarction; Diagnosis, Differential; Female; F | 1999 |
Homocyst(e)ine, vitamins and genetic interactions in vascular disease.
Topics: Arteriosclerosis; Female; Genotype; Homocysteine; Humans; Male; Middle Aged; Pyridoxine; Risk Factor | 1999 |
[Atherosclerosis. Congress of the European Atherosclerosis Society (EAS), Athens (Greece), 26-29 May 1999].
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Ascorbic Acid; Cholesterol, LDL; Diet; Eur | 1999 |
Extracellular magnesium regulates effects of vitamin B6, B12 and folate on homocysteinemia-induced depletion of intracellular free magnesium ions in canine cerebral vascular smooth muscle cells: possible relationship to [Ca2+]i, atherogenesis and stroke.
Topics: Animals; Arteriosclerosis; Basilar Artery; Calcium; Cells, Cultured; Cerebral Arteries; Dogs; Folic | 1999 |
Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature atherothrombotic cerebrovascular disease. A prospective cohort study.
Topics: Adult; Arteriosclerosis; Female; Folic Acid; Follow-Up Studies; Hematinics; Humans; Hyperhomocystein | 2000 |
[Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement].
Topics: Adult; Aged; Arteriosclerosis; Cysteine; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteine | 2000 |
Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Carotid Arteries; Cholesterol; Diet, Atherogenic; Diet | 2001 |
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cells, Cultured; Diet; Disease Models, Animal; Folic A | 2001 |
Homocysteine--an innocent bystander in vascular disease?
Topics: Arteriosclerosis; Biomarkers; Endothelium, Vascular; Homocysteine; Humans; Pyridoxine; Risk Factors; | 2001 |
Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Betaine; Betaine-Homocysteine S-Methyltransferase; | 2001 |
The aetiological role of maternal vitamin-B6 deficiency in the development of atherosclerosis.
Topics: Arteriosclerosis; Blood Vessels; Collagen; Elastin; Female; Humans; Infant, Newborn; Pregnancy; Preg | 1977 |
[Use of vitamin B6 in the overall treatment of elderly patients with primary dystrophies of the central portion of the fundus oculi].
Topics: Aged; Arteriosclerosis; Female; Fundus Oculi; Humans; Male; Middle Aged; Pyridoxine; Retinal Degener | 1978 |
Pyridoxine and atherosclerosis: role of pyridoxine in the metabolism of lipids and glycosaminoglycans in rats fed normal and high fat, high cholesterol diets containing 16% casein.
Topics: Animals; Aorta; Arteriosclerosis; Caseins; Cholesterol, Dietary; Diet, Atherogenic; Dietary Fats; Gl | 1978 |
Failure to produce atherosclerosis in Macaca radiata on a high-methionine, high-fat, pyridoxine-deficient diet.
Topics: Alanine Transaminase; Animals; Aorta; Arteriosclerosis; Aspartate Aminotransferases; Diet, Atherogen | 1977 |
[Effect of vitamin B 6 therapy on blood coagulation indicators in patients with arteriosclerotic dystrophy of macula lutea].
Topics: Adult; Arteriosclerosis; Blood Coagulation; Female; Humans; Macular Degeneration; Male; Middle Aged; | 1975 |
Lack of effect of vitamin B-6 supplementation on the lipoprotein profile of post-menopausal chronic hemodialysis patients.
Topics: Aged; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Lipoprotein | 1990 |
Delta-6-desaturase enzyme co-factors and atherosclerosis.
Topics: Animals; Arteriosclerosis; Cholesterol; Fatty Acid Desaturases; Humans; Linoleoyl-CoA Desaturase; Pr | 1985 |
Nutrition and atherosclerosis: some neglected aspects.
Topics: Arteriosclerosis; Ascorbic Acid; Ascorbic Acid Deficiency; Humans; Nutritional Physiological Phenome | 1985 |
[Effectiveness of treating coronary arteriosclerosis according to follow-up study data].
Topics: Adult; Aminophylline; Arteriosclerosis; Baths; Chronic Disease; Coronary Disease; Exercise Therapy; | 1973 |
[Pyridoxine adequacy in atherosclerotic cardiosclerosis and hypertension].
Topics: Alanine Transaminase; Arteriosclerosis; Aspartate Aminotransferases; Coronary Disease; Humans; Hyper | 1973 |
Vitamin contents of arterial tissue.
Topics: Aminobenzoates; Animals; Arteries; Arteriosclerosis; Ascorbic Acid; Biotin; Carotenoids; Chickens; C | 1973 |
[Effect of linodoxine treatment on the blood cholesterol and beta-lipoproteid level in arteriosclerotic patients].
Topics: Aged; Arteriosclerosis; Cholesterol; Fats, Unsaturated; Female; Humans; Lipids; Male; Middle Aged; P | 1964 |
Macromolecular basis for homocystein-induced changes in proteoglycan structure in growth and arteriosclerosis.
Topics: Arteriosclerosis; Cell Line; Cells, Cultured; Contact Inhibition; Cytoplasmic Granules; Growth Hormo | 1972 |
Chronic carbon disulfide poisoning.
Topics: Arteriosclerosis; Carbon Disulfide; Chronic Disease; Coronary Disease; Europe; Humans; Monoamine Oxi | 1972 |
[Action of a taurine-nucleotide-vitamin association on carbohydrate metabolism].
Topics: Adult; Aged; Arteriosclerosis; Biliary Tract Diseases; Carbohydrate Metabolism; Coronary Disease; Di | 1971 |
The tryptophan load as a test for pyridoxine deficiency in hospitalized patients.
Topics: Adult; Aged; Arteriosclerosis; Female; Gastrointestinal Diseases; Humans; Kynurenine; Male; Middle A | 1969 |
[Use in geriatrics of an association of taurine, nucleotides and vitamins].
Topics: Adult; Aged; Arteriosclerosis; Cerebrovascular Disorders; Dementia; Female; Hemiplegia; Humans; Hype | 1970 |
[Dynamic observations on the levels of vitamin B6 in patients with myocardial infarct].
Topics: Arteriosclerosis; Coronary Disease; Electrophoresis; Female; Humans; Liver; Male; Middle Aged; Myoca | 1968 |
[Effect of pyridoxine on the content of blood protein fractions in atherosclerosis patients].
Topics: Arteriosclerosis; Blood Proteins; Humans; Pyridoxine | 1965 |
Vitamin A,E,B6 and lipid metabolism: interrelationship in the rat.
Topics: Animals; Arteriosclerosis; Diet, Atherogenic; Female; Lipid Metabolism; Male; Pyridoxine; Rats; Vita | 1965 |
[The mechanism of action of vitamin B6 on lipid metabolism in atherosclerosis].
Topics: Animals; Arteriosclerosis; Cholesterol; Humans; Lipid Metabolism; Liver; Pyridoxine; Rabbits | 1965 |
[Therapeutic use of Pyridophylline in bronchopulmonary diseases in adults].
Topics: Adult; Aged; Arteriosclerosis; Humans; Middle Aged; Pyridoxine; Respiratory Tract Diseases; Theophyl | 1966 |
Influence of rabbit plasma on cellular lipoidosis in aortic culture of plasma donors.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Culture Techniques; Lipid Metabolism; Lipidoses; Male | 1966 |
Effect of linodoxine treatment on cholesterol and beta-lipoprotein levels in the blood serum of patients with atherosclerosis.
Topics: Aged; Arteriosclerosis; Cholesterol; Fatty Acids; Female; Humans; Lipoproteins; Male; Middle Aged; P | 1966 |